Pharmacogenomics of Warfarin dose requirements in Hispanics

Blood Cells, Molecules, and Diseases

Volumn 46, Issue 2, 2011, Pages 147-150

  Cavallari, Larisa H ^a   Momary, Kathryn M ^a,c   Patel, Shitalben R ^a   Shapiro, Nancy L ^a   Nutescu, Edith ^a   Viana, Marlos A G ^a,b  

^a Chicago College of Pharmacy   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c MERCER UNIVERSITY   (United States)

Author keywords

Cytochrome P450 2C9; Genotype; Hispanic; Vitamin K epoxide reductase; Warfarin

Indexed keywords

ADENINE; CYTOCHROME P450 2C9; GUANINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); WARFARIN;

ADULT; AGE; ARTICLE; BODY SURFACE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; MALE; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; UNITED STATES; VENOUS THROMBOEMBOLISM;

ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; UNITED STATES; WARFARIN;

EID: 79151476272     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.11.005     Document Type: Article

References (27)

1. Absher R.K., Moore M.E., Parker M.H. Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother. 2002, 36:1512-1517.
2. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008, 133:160S-198S.
3. Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
4. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
5. Wang D., Chen H., Momary K.M., Cavallari L.H., Johnson J.A., Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008, 112:1013-1021.
6. D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005, 105:645-649.
7. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 2005, 352:2285-2293.
8. Gage B.F., Eby C., Johnson J.A., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 2008, 84:326-331.
9. Veenstra D.L., You J.H., Rieder M.J., et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 2005, 15:687-691.
10. Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
11. Klein T.E., Altman R.B., Eriksson N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 2009, 360:753-764.
12. Coumadin (warfarin sodium) package insert 2010, Bristol-Myers Squibb, Princeton, NJ.
13. Hillman M.A., Wilke R.A., Caldwell M.D., Berg R.L., Glurich I., Burmester J.K. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004, 14:539-547.
14. Sconce E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333.
15. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570.
16. Herman D., Peternel P., Stegnar M., Breskvar K., Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 2006, 95:782-787.
17. U.S. Census Bureau, 1970, 1980, 1990, and 2000 Decennial Censuses; Population Projections, July 1, 2010 to July 1, 2050. www.census.gov. Accessed June 2010.
18. Wu A.H., Wang P., Smith A., et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008, 9:169-178.
19. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 2008, 358:999-1008.
20. Andrisin T.E., Humma L.M., Johnson J.A. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 2002, 22:954-960.
21. Hruska M.W., Frye R.F., Langaee T.Y. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin. Chem. 2004, 50:2392-2395.
22. Aquilante C.L., Langaee T.Y., Lopez L.M., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 2006, 79:291-302.
23. Schelleman H., Chen J., Chen Z., et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin. Pharmacol. Ther. 2008, 84:332-339.
24. Lubitz S.A., Scott S.A., Rothlauf E.B., et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 2010, 8:1018-1026.
25. Veenstra D.L., Blough D.K., Higashi M.K., et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 2005, 77:353-364.
26. Limdi N.A., Wadelius M., Cavallari L., et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010, 115:3827-3834.
27. Palacio L., Falla D., Tobon I., et al. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a Hispanic population isolate. Clin. Appl. Thromb. Hemost. 2010, 16:83-90.